O'Neal Comprehensive Cancer Center, University of Alabama

Birmingham, Alabama 35294

2 studies enrolling now · 2 studies all time

What they study most

Hematologic Malignancies, Pancreatic Ductal Adenocarcinoma (PDAC)

Studies at this site

• Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML — Recruiting now
• ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) — Recruiting now